利桑单抗在CD延迟反应患者中的维持率也较好

{"title":"利桑单抗在CD延迟反应患者中的维持率也较好","authors":"S. Kammerer","doi":"10.55788/6205580f","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":119347,"journal":{"name":"Medicom Conference Report UEGW 2022","volume":"35 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Favourable maintenance rates for risankizumab also in delayed responders with CD\",\"authors\":\"S. Kammerer\",\"doi\":\"10.55788/6205580f\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":119347,\"journal\":{\"name\":\"Medicom Conference Report UEGW 2022\",\"volume\":\"35 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicom Conference Report UEGW 2022\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55788/6205580f\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicom Conference Report UEGW 2022","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55788/6205580f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}